This result was consistent with that obtained from the autochthonous WAP-Cre;Brca1-deficient model (Fig. 3), substantiating the conclusion that the anti-cancer efficacy of ZMC1 is specific to mutant p53R172H. The gene discussed is BRCA1; the disease is cancer.